Observational study on invasive Group A streptococcal infections in children across Europe
PEGASUS: Paediatric European Group A Streptococcal United Study.
This study is trying to understand how common serious Group A strep infections are in children across Europe and what factors might affect their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 0 Years to 18 Years |
| Sex | All |
| Sponsor | Noordwest Ziekenhuisgroep Academic / other |
| Locations | 1 site (Alkmaar, NH) |
| Trial ID | NCT06058117 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a European research network to investigate the incidence, risk factors, clinical characteristics, microbiology, treatment, and outcomes of invasive Group A beta-haemolytic streptococcal disease (iGAS) in children aged 0-18 years. By collecting data from children attending emergency departments or hospitalized with iGAS or other invasive infections, the study seeks to provide insights into the rising trends of these infections and facilitate early alerts for emerging infectious diseases. The methodology involves a retrospective cohort analysis and observational surveillance across multiple European countries.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 1 month to 18 years who are attending the emergency department or are admitted to the hospital with iGAS or other invasive infectious diseases.
Not a fit: Patients who do not have invasive Group A streptococcal infections or other emergent infectious diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of iGAS in children, leading to improved prevention and treatment strategies.
How similar studies have performed: While there have been studies on invasive infections in children, this specific approach to establishing a European network for iGAS is novel and aims to address a recent increase in cases.
Eligibility criteria
Show full inclusion / exclusion criteria
* All children (1 month-18 years) * attending the Emergency Department and/or admitted to the participating hospital - with iGAS infection or other invasive or emergent infectious disease.
Where this trial is running
Alkmaar, NH
- Noordwest Ziekenhuisgroep — Alkmaar, Nh, Netherlands (Recruiting)
Study contacts
- Study coordinator: Dorine Borensztajn, MD, PhD, MSc
- Email: dm.borensztajn@nwz.nl
- Phone: +31880855262
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.